Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045
Debt
Debt-to-Equity RatioN/A
Current Ratio33.93
Quick Ratio33.93
Price-To-Earnings
Trailing P/E Ratio4.02
Forward P/E Ratio-7.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$143.89 million
Price / Sales2.67
Cash Flow$4.2351 per share
Price / Cash3.87
Book Value$8.55 per share
Price / Book1.92
Profitability
EPS (Most Recent Fiscal Year)$4.08
Net Income$95.63 million
Net Margins67.52%
Return on Equity-19.73%
Return on Assets-18.17%
Miscellaneous
Employees64
Outstanding Shares23,420,000
Market Cap$384.24 million
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) announced its earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.62) by $0.05. Concert Pharmaceuticals had a net margin of 67.52% and a negative return on equity of 19.73%. View Concert Pharmaceuticals' Earnings History.
When is Concert Pharmaceuticals' next earnings date?
What price target have analysts set for CNCE?
4 equities research analysts have issued 1-year target prices for Concert Pharmaceuticals' shares. Their predictions range from $26.00 to $34.00. On average, they expect Concert Pharmaceuticals' share price to reach $28.50 in the next year. This suggests a possible upside of 73.9% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.
What is the consensus analysts' recommendation for Concert Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. More importantly, Concert continues its steady progress on the clinical development front. A key catalyst is expected in 4Q18 with top-line readouts from the phase 2a trial of CTP-543 in alopecia areata at the 4 mg and 8 mg doses. A protocol amendment is also planned to evaluate the highest 12 mg dose. We anticipate data from the high-dose cohort will likely read out in 4Q19." (8/2/2018)
- 2. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (5/2/2018)
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Corcept Therapeutics (CORT), ARMO Biosciences (ARMO), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), TESARO (TSRO), Myovant Sciences (MYOV), IMMURON Ltd/S (IMRN), Innoviva (INVA), Impax Laboratories (IPXL), Deciphera Pharmaceuticals (DCPH), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR), Uniqure (QURE), Biohaven Pharmaceutical (BHVN) and Wave Life Sciences (WVE).
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich, Co-Founder & Chairman (Age 64)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 58)
- Ms. Nancy Stuart, Chief Operating Officer (Age 60)
- Dr. James V. Cassella, Chief Devel. Officer (Age 63)
- Mr. Marc A. Becker, Chief Financial Officer (Age 46)
Has Concert Pharmaceuticals been receiving favorable news coverage?
News stories about CNCE stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a media and rumor sentiment score of 0.10 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.07 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Concert Pharmaceuticals.
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.99%), Ingalls & Snyder LLC (5.71%), Dimensional Fund Advisors LP (4.03%), Acadian Asset Management LLC (4.02%), Renaissance Technologies LLC (2.59%) and Connor Clark & Lunn Investment Management Ltd. (1.77%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Nancy Stuart, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which institutional investors are selling Concert Pharmaceuticals stock?
CNCE stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Russell Investments Group Ltd., Citadel Advisors LLC, Fisher Asset Management LLC, Spark Investment Management LLC, BlueMountain Capital Management LLC, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include James V Cassella, Nancy Stuart, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.
Which institutional investors are buying Concert Pharmaceuticals stock?
CNCE stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, GSA Capital Partners LLP, Renaissance Technologies LLC, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., Foundry Partners LLC and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $16.39.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $384.24 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
